RIPK1 and atherosclerosis: Therefore, the mono-selective, new generation RIPK1 kinase inhibitor GSK’547 was included in the present study to treat atherosclerotic ApoE−/− Fbn1C1039G+/− mice, which is a model of advanced, human-like atherosclerosis.